Genmab — November 2018

[Solsen]

Imponerende !!!

[E_L]

sure is, Jan will be proud

[E_L]

To prove the anti-leukemic activity of daratumumab in AML in vivo https://ash.confex.com/ash/2018/webprogram/Paper113287.html

[StockBull]

Firework and champagne

[bibob]

Sagde han ikke også at de ville komme til at dominere ASH

[Bulder]

Lyra er med som oral!

[StockBull]

dominere i antal ser det ud til - forhåbentlig også i kvalitet af data

[E_L]

Conclusions: CyBorD-DARA is a highly active, well tolerated induction therapy for NDMM patients undergoing ASCT. https://ash.confex.com/ash/2018/webprogram/Paper112375.html

[bibob]

Vel ingen grund til at præsentere hvis data er dårlige

[E_L]

Conclusions:
CyBorD-DARA is a highly active, well tolerated induction therapy for NDMM patients undergoing ASCT. https://ash.confex.com/ash/2018/webprogram/Paper112375.html

[E_L]

Lyra : https://ash.confex.com/ash/2018/webprogram/Paper110310.html

[Solsen]

Addition of tretinoin (ATRA) induced a ~4-fold increase of CD38 expression in AML blasts and to a lower extent in normal donor cells. In fact, combination of tretinoin and daratumumab led to an enhanced anti-leukemic activity in AML - Vi mangler i den grad in vivo data og burde vel have dem nu !

[E_L]

we need some volunteers to just throw this into the clinic!

[Bulder]

Lyra har betydeligt ringere vgpr+ rate end Griffin. Tyder på at dara + Cybord bliver en parentes, bortset fra de lande, hvor der ikke råd til andet.

[Bulder]

De pusler stadig med at rette algoritmen i de robotter der sendte genmab ned sammen med Coloplast

[gentogen]

ADCT 301: In the 45 µg/kg dose group (dose escalation + expansion), the ORR was 80.8% (21/26 pts) and the CR rate was 50% (13/26 pts

[gentogen]

Conclusions: In pts with R/R cHL, therapy with Cami-T provided impressive ORRs and CR rates in a heavily pretreated pt population

[E_L]

sounds good!

[Bulder]

stærkt gentogen

[Parasitism]

https://www.nordnet.dk/mux/web/analys/nyheter/visaNyhet.html?itemid=326503009&sourcecode=hugin